Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-14 1:00 pm Purchase | 13G | RUBIUS THERAPEUTICS INC RUBY | Flagship VentureLabs IV LLC | 38,606,526 42.700% | 38,606,526 (New Position) | View |
| 2022-10-17 4:32 pm Purchase | 13D | AXCELLA HEALTH INC AXLA | Flagship VentureLabs IV LLC | 29,251,545 39.800% | 10,383,760 (+55.03%) | View |
| 2022-09-23 4:31 pm Unchanged | 13D | AXCELLA HEALTH INC AXLA | Flagship VentureLabs IV LLC | 18,867,785 35.800% | 0 (Unchanged) | View |
| 2022-07-07 5:00 pm Purchase | 13D | Seres Therapeutics Inc. MCRB | Flagship VentureLabs IV LLC | 23,493,063 18.900% | 8,443,072 (+56.10%) | View |
| 2022-03-18 08:30 am Purchase | 13D | AXCELLA HEALTH INC AXLA | Flagship VentureLabs IV LLC | 18,867,785 36.400% | 6,319,371 (+50.36%) | View |
| 2020-11-25 4:30 pm Sale | 13D | Seres Therapeutics Inc. MCRB | Flagship VentureLabs IV LLC | 15,049,991 16.500% | -6,596,914 (-30.48%) | View |
| 2020-05-20 5:00 pm Purchase | 13D | AXCELLA HEALTH INC AXLA | Flagship VentureLabs IV LLC | 12,548,414 35.000% | 3,800,000 (+43.44%) | View |